Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Prof Angela Russell has been named as a ‘Rising Star’ in the BioBeat 50 Movers and Shakers in BioBusiness 2016 report.

Released annually, the report celebrates 50 outstanding women entrepreneurs and business leaders who are recognised for their contributions to global health innovation.  BioBeat’s founder Miranda Weston-Smith said that the report highlights those women who are “transforming today’s challenges into tomorrow’s opportunities” and are inspirational “pioneers who are setting the pace in laboratories, healthcare, entrepreneurial companies …“ among others. 

Angela Russell, Associate Professor of Medicinal Chemistry at the Departments of Chemistry and Pharmacology at the University of Oxford and co-founder of OxStem Ltd said “I am delighted to have been recognised in this report standing alongside some exceptional bioscience business leaders in the field.  Our research at OxStem has the potential to impact on the healthcare of millions worldwide with the approach of developing small molecule drugs in a wide range of therapeutic areas including cancer, neurodegenerative diseases and heart failure.  I hope that my nomination, together with the women featured in this report, helps to inspire the next generation of bioscience entrepreneurs”.

BioBeat 50 Movers and Shakers in BioBusiness 2016 report

Angela Russell, Associate Professor of Medicinal Chemistry, University of Oxford and Co-founder OxStem. Launched in May 2016, Angela co-founded OxStem, a revolutionary University of Oxford spin-out company focussed on regenerative medicine. OxStem aims to identify new classes of drugs that can reprogram or stimulate existing resident cells to repair tissues in age-related conditions including cancer, neurodegenerative diseases and heart failure. The company has raised £16.9 million this year, a record for a UK spin-out, to fund the development of a series of daughter companies.

In her academic career, with over 15 years medicinal chemistry experience, Angela has published over 80 original articles, book chapters and patent applications and co-founded the Oxford spin-out MuOx Ltd, acquired by Summit Therapeutics plc in 2013.

Similar stories

Smoking increases the risks of 56 diseases in Chinese adults

Smoking increases the risks of 56 diseases and kills more than one million adults in China each year from 22 different causes, according to new research published in The Lancet Public Health.

Success for Oxford researchers in The Genetics Society 2023 Awards

Researchers from Department of Physiology, Anatomy and Genetics, Radcliffe Department of Medicine and Nuffield Department of Population Health have been recgonised in The Genetics Society 2023 awards.

New Studentship honours Enzo Cerundolo

A new Studentship has been announced in memory of the late MRC HIU Director and MRC WIMM Group Leader.

Young lives under pressure as global crises hits mental health and well-being – report

The well-being and mental health of young people in low - and middle - income countries have been dramatically affected by the series of crises hitting the world. As the international community continues to struggle with the impact of COVID-19, conflict and climate change, the latest report from the Young Lives project shows a long-running upward trend in young people’s well-being has been sharply reversed alongside widespread anxiety and depression. Young people are less confident about their futures for the first time in the 20-year study.

Bacterial infections linked to one in eight global deaths, according to GRAM study

Data showing 7.7 million deaths from 33 bacterial infections can guide measures to strengthen health systems, particularly in low-income settings